Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.
about
Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancerFactors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression AnalysisThe impact of overweight and obesity on breast cancer: data from Switzerland, so far a country little affected by the current global obesity epidemicOral antineoplastic agents: how do we care about adherence?Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part DAdjuvant therapy use among Appalachian breast cancer survivorsCYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive EarlyAdherence with capecitabine: A population-based analysis based on prescription refill data.Predicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory.A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12)American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.Pain in cancer survivorsOptimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivorsAdherence to hormone therapy among women with breast cancerMedicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy.Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization : Analysis of a medical claims database.A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL).Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancerRacial disparities in initiation of adjuvant endocrine therapy of early breast cancer.Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients.Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect RatioEarly discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients.Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patientsThe tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.Quality of life among a population-based cohort of older patients with breast cancer.Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patientsCognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study.Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associationsProspective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.Perspectives on adherence and persistence with oral medications for cancer treatment.Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
P2860
Q24632347-6E2769B0-43B6-4848-858B-C113E7D84C17Q26779595-A56DDD6C-8880-486B-BCA8-553C1553420CQ27021293-FD90B006-65B7-4CFC-809D-FACB8AF16F79Q28082909-726C1878-93EF-4028-A111-C567AE6ECC56Q28657951-7B846F30-4A3B-44C1-B07B-AF1E0882480CQ30279083-7EC6517C-5D20-47FA-B3F7-E619778851A6Q30400967-DDA43B03-F525-4EEF-81B0-A6EA3A567FFDQ30732631-BC20B3AB-AED2-47F9-9A55-FB8D4B5D6936Q31140272-0E45D129-A13E-40FE-992F-43B614111437Q33562869-ACDE96B0-8DE3-4077-8ABE-693980880A7EQ33618145-DD6E36B1-DA06-42F1-9873-AD14689EDF0DQ33631047-5492BCD3-4247-4086-98CF-94A346E24662Q33650576-7C3E724E-4503-48B7-92E4-007A0D2BB203Q33698446-42B932C3-6017-43F7-BC07-B76B7644362EQ33714141-CF0D3516-C9FF-40C6-895E-BD13A854BF25Q33755452-6EB06BA5-EB3C-4D5E-91E5-762DD543F9F8Q33756382-8670269D-C60A-474D-A88D-AEA886FAF299Q33756969-A71C8B55-CF68-4346-A514-A0DA0A1D7D14Q33793932-8094D734-10D0-4782-9BFB-765ADA87A42EQ33818100-1F5AB497-A147-46AC-996B-FFD4F7DFE55BQ33841309-7A79118F-FFA4-41BC-9F82-E1F3AFB250B6Q33857602-DBB1E964-AD62-42F3-8B74-A970F27551FDQ33874887-C9D5D1BF-526D-4953-A4CF-E91A95AD5284Q33877830-8137EDBC-2656-47C9-88F2-27EBC817E8B1Q33897610-B3ECE4A0-9C49-4F78-809F-F4B306AD8339Q33941574-08C50164-B3DB-45F7-AC7E-2284AE0CEBA1Q34007066-C5B1972F-0E5F-497B-9D39-3F87A8BA8BF3Q34020925-296E939A-1D01-455E-B63A-5ACDAA98DE30Q34095816-E0ED448A-BE12-436C-BB06-C069CDC74934Q34174599-7FF15FDB-9AC0-4C90-9378-423B0C58D1C6Q34193946-836BE565-5C61-42B8-BCD8-CF331971BF3DQ34205869-2232FB05-0639-4DF5-BB47-0F8EBCB36476Q34279148-DB31CA30-8D06-4703-9EF0-AA32BDF291ABQ34287873-3548D399-7CC4-4A9C-ADA5-2970B26F4CFEQ34346501-43BEB882-B113-42D0-B46D-8C90039E3FF9Q34402534-F1FBAF2D-7B70-4D65-B6A3-76CACC11C409Q34423538-B538D08D-D5A2-4A1A-96BD-41B8324AB371Q34434858-E8525FE9-BA8E-4B0A-BFC2-8EE3AABEE1E7Q34459748-D5EA647B-0075-4F59-B490-BFF76B1AA9B3Q34488758-5710D17E-B217-42C5-AEAE-97B71AC81AC6
P2860
Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Adherence to initial adjuvant ...... ith early-stage breast cancer.
@en
type
label
Adherence to initial adjuvant ...... ith early-stage breast cancer.
@en
prefLabel
Adherence to initial adjuvant ...... ith early-stage breast cancer.
@en
P2093
P356
P1476
Adherence to initial adjuvant ...... ith early-stage breast cancer.
@en
P2093
Andrea LaFountain
Ann H Partridge
Aviva Asnis-Alibozek
Brooke S Taylor
Eric Winer
Erica Mayer
P304
P356
10.1200/JCO.2007.11.5451
P407
P577
2008-01-07T00:00:00Z